Expert Answer
Quick Answer
There's no single "normal" — the experts who cover ApoB argue for lower than standard labs call normal. Attia targets roughly 60 mg/dL for people in their late 30s-40s and points to the much lower levels seen in children (around 20-40 mg/dL) as the biological benchmark. ApoB counts atherogenic particles, and lowering it is a physician-guided decision.
Strong Consensus
on ApoB overall
Champions ApoB as a more accurate risk marker than LDL-C because it counts all atherogenic particles; targets ~60 mg/dL for late 30s/40s and cites childhood-low ApoB (~20-40 mg/dL) as the benchmark, using diet plus pharmacology — explicitly physician-supervised.
Recommends advanced lipid testing (ApoB, Lp(a)) over standard LDL, noting many heart-attack victims have "normal" LDL — so a normal LDL doesn't mean a safe ApoB.
Treats ApoB particle burden, not just cholesterol level, as the metric that drives atherosclerosis risk.
Surfaces ApoB as a key, trackable risk factor to measure early in life (in conversation with Attia).
No direct ApoB coverage in the analyzed videos.
There isn't one universal "good" number, but the experts who cover ApoB agree on the direction: aim lower than the lab's "normal" flag. ApoB measures the NUMBER of atherogenic particles (LDL, VLDL, Lp(a)) rather than the cholesterol mass they carry — which is why Attia, Patrick, and Huberman treat it as a more complete picture of cardiovascular risk than LDL-C.
Attia is the most specific. He argues for early, aggressive lowering and points to two reference points: the much lower ApoB levels seen in children (he cites roughly 20-40 mg/dL) as a safety/efficacy benchmark, and a working ceiling around 60 mg/dL for people in their late 30s and early 40s. His reasoning is that ApoB is a causal driver of atherosclerosis (citing Mendelian randomization), and standard 10-year risk calculators lean on age and sex while ignoring the underlying disease — so he'd rather measure ApoB directly and act early. He's explicit that hitting low targets often takes diet plus medication (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) under a doctor's care.
Hyman reaches a similar place from the metabolic side: advanced lipid particle analysis (ApoB, Lp(a)) beats a standard panel, and a "normal" LDL can hide an unsafe particle count — many heart-attack victims have normal LDL. Two honest caveats: ApoB often isn't on a basic cholesterol panel, so you may have to request advanced lipid testing; and this is educational synthesis, not medical advice — what your target should be, and whether to add medication, is a decision for your physician.
Attia targets roughly 60 mg/dL for people in their late 30s-40s and cites childhood-low levels (~20-40 mg/dL) as the benchmark — lower than most labs flag as normal. Targets are individual and physician-guided.
The experts who cover it say yes — ApoB counts atherogenic particles (LDL, VLDL, Lp(a)) rather than estimating cholesterol mass, which Attia, Patrick, and Hyman call a more accurate risk marker than LDL-C.
Yes — Hyman notes many heart-attack victims have "normal" LDL. That's why he and Attia push for measuring ApoB directly rather than trusting a standard panel.
Diet (less saturated fat and refined carbohydrate) helps but is often insufficient to reach optimal targets per Attia, who adds physician-prescribed medication. Any drug decision belongs with your doctor.
This page covers what researchers agree on. Pro gives you the specific dosages, timing schedules, and interaction warnings they each recommend — with video citations you can verify.
Cancel anytime
Full ApoB Consensus Report
See what all the experts agree and disagree on